Psychiatric Drug Discovery

Revolution Stalled

Science Translational Medicine
10 Oct 2012
Vol 4, Issue 155
p. 155cm11


Drug discovery is at a near standstill for treating psychiatric disorders such as schizophrenia, bipolar disorder, depression, and common forms of autism. Despite high prevalence and unmet medical need, major pharmaceutical companies are deemphasizing or exiting psychiatry, thus removing significant capacity from efforts to discover new medicines. In this Commentary, I develop a view of what has gone wrong scientifically and ask what can be done to address this parlous situation.

Get full access to this article

View all available purchase options and get full access to this article.

Already a subscriber or AAAS Member?

References and Notes

Kessler R. C., Chiu W. T., Demler O., Merikangas K. R., Walters E. E., Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617–627 (2005).
World Health Organization, The Global Burden of Disease. 2004 Update. (World Health Organization. Geneva 2008).
Minzenberg M. J., Carter C. S., Developing treatments for impaired cognition in schizophrenia. Trends Cogn. Sci. 16, 35–42 (2012).
Holtzheimer P. E., Mayberg H. S., Deep brain stimulation for psychiatric disorders. Annu. Rev. Neurosci. 34, 289–307 (2011).
Miller G., Is pharma running out of brainy ideas? Science 329, 502–504 (2010).
Abbott A., Novartis to shut brain research facility. Nature 480, 161–162 (2011).
Axelrod J., Whitby L. G., Hertting G., Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues. Science 133, 383–384 (1961).
Rush A. J., Trivedi M. H., Wisniewski S. R., Nierenberg A. A., Stewart J. W., Warden D., Niederehe G., Thase M. E., Lavori P. W., Lebowitz B. D., McGrath P. J., Rosenbaum J. F., Sackeim H. A., Kupfer D. J., Luther J., Fava M., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am. J. Psychiatry 163, 1905–1917 (2006).
Sachs G. S., Nierenberg A. A., Calabrese J. R., Marangell L. B., Wisniewski S. R., Gyulai L., Friedman E. S., Bowden C. L., Fossey M. D., Ostacher M. J., Ketter T. A., Patel J., Hauser P., Rapport D., Martinez J. M., Allen M. H., Miklowitz D. J., Otto M. W., Dennehy E. B., Thase M. E., Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med. 356, 1711–1722 (2007).
Kane J., Honigfeld G., Singer J., Meltzer H., Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45, 789–796 (1988).
Hyman S. E., Fenton W. S., Medicine. What are the right targets for psychopharmacology? Science 299, 350–351 (2003).
Heinrichs R. W., Cognitive improvement in response to antipsychotic drugs: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 631–632 (2007).
E. J. Nestler, S. E. Hyman, R. J. Malenka, Molecular Neuropharmacology: Foundation for Clinical Neuroscience (McGraw, Hill, New York, 2009).
Zarate C. A., Singh J. B., Carlson P. J., Brutsche N. E., Ameli R., Luckenbaugh D. A., Charney D. S., Manji H. K., A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856–864 (2006).
Lieberman J. A., Stroup T. S., McEvoy J. P., Swartz M. S., Rosenheck R. A., Perkins D. O., Keefe R. S., Davis S. M., Davis C. E., Lebowitz B. D., Severe J., Hsiao J. K.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209–1223 (2005).
Nestler E. J., Hyman S. E., Animal models of neuropsychiatric disorders. Nat. Neurosci. 13, 1161–1169 (2010).
Seligman M. E. P., Learned helplessness. Annu. Rev. Med. 23, 407–412 (1972).
National Center for Biotechnology Information of the US National Library of Medicine, Consulted 25 August 2012.
Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, A mega-analysis of genome-wide association studies for major depressive disorder. Mol. Psychiatry. Published online 3 April 2012.
T. S. Kuhn, The Structure of Scientific Revolutions (Univ. Chicago Press, Chicago, ed. 2, 1962).
DiMasi J. A., Feldman L., Seckler A., Wilson A., Trends in risks associated with new drug development: Success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272–277 (2010).
D. J. Carlat, Unhinged: The Trouble with Psychiatry (Free Press, New York, 2010).
Hyman S. E., Can neuroscience be integrated into the DSM-V? Nat. Rev. Neurosci. 8, 725–732 (2007).
Konopka G., Friedrich T., Davis-Turak J., Winden K., Oldham M. C., Gao F., Chen L., Wang G. Z., Luo R., Preuss T. M., Geschwind D. H., Human-specific transcriptional networks in the brain. Neuron 75, 601–617 (2012).
Fernando A. B. P., Robbins T. W., Animal models of neuropsychiatric disorders. Annu. Rev. Clin. Psychol. 7, 39–61 (2011).
Peça J., Feliciano C., Ting J. T., Wang W., Wells M. F., Venkatraman T. N., Lascola C. D., Fu Z., Feng G., Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472, 437–442 (2011).
Krueger D. D., Bear M. F., Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62, 411–429 (2011).
Sullivan P. F., Daly M. J., O’Donovan M., Genetic architectures of psychiatric disorders: The emerging picture and its implications. Nat. Rev. Genet. 13, 537–551 (2012).
Yizhar O., Fenno L. E., Davidson T. J., Mogri M., Deisseroth K., Optogenetics in neural systems. Neuron 71, 9–34 (2011).
Ting J. T., Peça J., Feng G., Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders. Annu. Rev. Neurosci. 35, 49–71 (2012).
Kirov G., Pocklington A. J., Holmans P., Ivanov D., Ikeda M., Ruderfer D., Moran J., Chambert K., Toncheva D., Georgieva L., Grozeva D., Fjodorova M., Wollerton R., Rees E., Nikolov I., van de Lagemaat L. N., Bayés A., Fernandez E., Olason P. I., Böttcher Y., Komiyama N. H., Collins M. O., Choudhary J., Stefansson K., Stefansson H., Grant S. G., Purcell S., Sklar P., O’Donovan M. C., Owen M. J., De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 17, 142–153 (2012).
Brennand K. J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., Li Y., Mu Y., Chen G., Yu D., McCarthy S., Sebat J., Gage F. H., Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221–225 (2011).
Zhang F., Cong L., Lodato S., Kosuri S., Church G. M., Arlotta P., Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat. Biotechnol. 29, 149–153 (2011).

Information & Authors


Published In

Science Translational Medicine
Volume 4 | Issue 155
October 2012


Request permissions for this article.


I thank the members and staff of the Institute of Medicine Forum on Neuroscience and Nervous System Disorders for multiple probing discussions touching on many of the topics discussed here. Funding: This work was supported by the Stanley Foundation. Competing interests: I serve on the Novartis Science Board.



Steven E. Hyman
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.


Metrics & Citations


Article Usage


Export citation

Select the format you want to export the citation of this publication.

Cited by

  1. A Randomized Controlled Trial of Computerized Interpretation Bias Training for Disruptive Mood Dysregulation Disorder: A Fast-Fail Study, Journal of the American Academy of Child & Adolescent Psychiatry, (2021).
  2. Wringing Biological Insight From Polygenic Signals, Biological Psychiatry, 89, 1, (8-10), (2021).
  3. Across-subjects multiple baseline trial of exposure-based cognitive-behavioral therapy for severe irritability: a study protocol, BMJ Open, 11, 3, (e039169), (2021).
  4. Systematic Reviews of Animal Studies, Principles and Practice of Systematic Reviews and Meta-Analysis, (177-188), (2021).
  5. The Importance of Common Currency Tasks in Translational Psychiatry, Current Behavioral Neuroscience Reports, 8, 1, (1-10), (2021).
  6. Cognitive effects of rapid-acting treatments for resistant depression: Just adverse, or contributing to clinical efficacy?, Journal of Psychiatric Research, 140, (512-521), (2021).
  7. How brain single photon emission computed topography imaging informs the diagnosis and treatment of mood disorders, The Neuroscience of Depression, (267-275), (2021).
  8. Biomarkers and neurobehavioral diagnosis, Biomarkers in Neuropsychiatry, 4, (100029), (2021).
  9. Exploring the crosstalk of glycolysis and mitochondrial metabolism in psychiatric disorders and brain tumours, European Journal of Neuroscience, 53, 9, (3002-3018), (2021).
  10. The forced swim test has poor accuracy for identifying novel antidepressants, Drug Discovery Today, (2021).
  11. See more

View Options

Get Access

Log in to view the full text


AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.

Log in via OpenAthens.
Log in via Shibboleth.

More options

Purchase digital access to this article

Download and print this article for your personal scholarly, research, and educational use.

View options

PDF format

Download this article as a PDF file

Download PDF







Share article link

Share on social media